Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enavogliflozin Cardio-Renal Outcomes in Type 2 Diabetes Mellitus
KCT0009243Phase 4Recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of enavogliflozin in type 2 diabetes mellitus (T2DM), sponsored by Daewoong Pharmaceutical. Started Jan 2024; status: recruiting.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on KCT0009243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009243.